Prevalence of Stroke in People with Multiple Sclerosis
International Journal of Preventive Medicine,
Год журнала:
2025,
Номер
16
Опубликована: Фев. 1, 2025
Язык: Английский
When Potassium Takes a Break: A Case Series of 3 Cases on Hypokalemic Periodic Paralysis
Clinical Case Reports,
Год журнала:
2025,
Номер
13(5)
Опубликована: Апрель 29, 2025
This
case
series
highlights
three
SHPP
cases
with
varied
triggers,
managed
potassium
supplementation
and
targeted
treatments.
Early
diagnosis,
individualized
care,
patient
education
proved
vital
in
preventing
recurrence
complications,
emphasizing
the
need
for
clinical
vigilance
tailored
approaches
HPP
management.
Язык: Английский
Risk of stroke under disease modifying therapies for multiple sclerosis: a systematic review
Therapeutic Advances in Neurological Disorders,
Год журнала:
2025,
Номер
18
Опубликована: Янв. 1, 2025
Background:
Epidemiological
research
indicates
a
heightened
incidence
of
cerebrovascular
disorders
among
patients
with
multiple
sclerosis
(MS).
Objectives:
The
aim
the
present
systematic
review
was
to
investigate
potential
association
between
disease
modifying
therapies
(DMTs)
and
risk
stroke
in
MS
patient
populations.
Data
sources
methods:
A
literature
search
performed
MEDLINE
SCOPUS
databases
up
April
6,
2024,
identify
randomized-controlled
clinical
trials
(RCT),
registry-based
cohort-studies,
case-series,
case-reports
reporting
on
acute
ischemic
(AIS)
or
intracerebral
hemorrhage
(ICH)
under
different
DMTs.
Results:
Twenty-one
studies
were
included:
1
RCT,
6
cohort
studies,
2
case-series
11
case-reports.
Overall,
DMTs
appear
reduce
patients,
DMT
exposure
linked
50%
reduction
compared
no
exposure.
Although
glatiramer
acetate
dimethyl
fumarate
lower
stroke,
concerns
about
fingolimod
exists
due
an
observed
elevated
for
heart
hypertension.
Despite
absence
detected
safety
alemtuzumab
at
population
level,
alemtuzumab-related
complications,
although
rare,
signal
need
vigilance.
Similarly,
β-interferons
have
been
life-threatening
adverse
events,
comprising
thrombotic
thrombocytopenic
purpura-hemolytic
uremic
syndrome
(TTP-HUS).
No
associations
other
DMTs,
natalizumab
teriflunomide,
detected;
yet,
newly
approved
underrepresented.
Conclusion:
These
findings
highlight
importance
personalizing
selection
monitoring
cardiovascular
factors
MS.
Trial
registration:
PROSPERO
CRD42024534470.
Язык: Английский
Neuroimaging biomarkers for predicting stroke outcomes: A systematic review
Health Science Reports,
Год журнала:
2024,
Номер
7(7)
Опубликована: Июль 1, 2024
Abstract
Background
and
Aims
Stroke
is
a
prominent
cause
of
long‐term
adult
impairment
globally
significant
global
health
issue.
Only
14%
stroke
survivors
achieve
full
recovery,
while
25%
to
50%
require
varying
degrees
support,
over
half
become
dependent.
The
aftermath
brings
profound
changes
an
individual's
life,
with
early
choices
significantly
impacting
their
quality
life.
This
review
aims
establish
the
efficacy
neuroimaging
data
in
predicting
outcomes
recovery
rates
following
stroke.
Methods
A
scientific
literature
search
was
conducted
using
Centre
Reviews
Dissemination
(CRD)
criteria
PRISMA
guidelines
for
combined
meta‐narrative
systematic
quantitative
review.
methodology
involved
structured
databases
like
PubMed
Cochrane
Library,
inclusion
exclusion
identify
relevant
studies
on
biomarkers
outcome
prediction.
Data
collection
utilized
Microsoft
Edge
Zotero
plugin,
appraisal
via
CASP
checklist.
Studies
published
from
2010
2024,
including
observational,
randomized
control
trials,
case
reports,
clinical
trials.
Non‐English
incomplete
were
excluded,
resulting
identification
11
pertinent
articles.
extraction
emphasized
study
methodologies,
conditions,
parameters,
biomarkers,
aiming
provide
thorough
overview
evaluate
significance
outcomes.
Results
results
this
indicate
that
integrating
advanced
methods
highly
successful
reperfusion
therapies
facilitates
diagnosis
condition
assists
improving
neurological
impairments
These
measures
reduce
possibility
death
improve
treatment
provided
patients.
Conclusion
findings
highlight
crucial
role
advancing
our
understanding
post‐stroke
patient
care.
Язык: Английский
Carotid intima-media thickness and risk of atherosclerosis in multiple sclerosis: A cross-sectional study
PLoS ONE,
Год журнала:
2024,
Номер
19(11), С. e0314031 - e0314031
Опубликована: Ноя. 19, 2024
Background
Multiple
sclerosis
(MS)
is
characterized
by
inflammation
and
demyelination
in
the
central
nervous
system.
Recent
studies
have
suggested
a
potential
association
between
MS
an
increased
risk
of
atherosclerosis,
systemic
vascular
disease
involving
arterial
wall
thickening.
Understanding
this
relationship
crucial,
given
heightened
cardiovascular
observed
patients.
Objective
To
investigate
factors
influencing
development
atherosclerosis
patients
with
multiple
(pwMS),
focusing
on
carotid
intima-media
thickness
(CIMT)
as
marker.
Methods
114
pwMS
(82
females
32
males)
127
control
subjects
(57
70
were
included.
The
mean
CIMT
two
groups
was
compared.
Additionally,
effects
annual
relapse
rate,
EDSS
(Expanded
Disability
Status
Scale),
duration,
treatment
type
Disease-modifying
(DMT)
evaluated.
Results
This
study
included
241
participants
(SD)
age
41.13
years
(10.93).
significantly
higher
compared
to
controls
(
p
<
0.001).
Even
after
adjusting
for
age,
sex,
BMI
(Body
Mass
Index),
remained
group
Spearman’s
correlation
analysis
revealed
significant
associations
BMI,
score,
duration
(all
0.05).
SPMS
(Secondary
Progressive
Sclerosis)
course
associated
Linear
regression
identified
most
predictor
0.001),
followed
=
0.054).
Conclusion
demonstrates
CIMT.
emerged
prominent
high
pwMS,
BMI.
These
findings
suggest
link
risk.
Further
research
warranted
explore
underlying
mechanisms
long-term
outcomes
population.
Язык: Английский
Multiple sclerosis and vascular nexus: A systematic review and meta-analysis of incidence and mortality
Revue Neurologique,
Год журнала:
2024,
Номер
unknown
Опубликована: Дек. 1, 2024
Язык: Английский
Cardiac effects and comorbidities of neurological diseases
TURKISH JOURNAL OF MEDICAL SCIENCES,
Год журнала:
2024,
Номер
54(7), С. 1428 - 1437
Опубликована: Дек. 13, 2024
Neurological
disorders
encompass
a
complex
and
heterogeneous
spectrum
of
diseases
affecting
the
brain,
spinal
cord,
peripheral
nervous
system,
each
presenting
unique
challenges
that
extend
well
beyond
primary
neurological
symptoms.
These
profoundly
impact
cardiovascular
health,
prompting
an
intensified
exploration
into
intricate
interconnections
between
systems.
This
review
synthesizes
current
insights
research
on
comorbidities
associated
with
major
conditions,
including
stroke,
epilepsy,
Parkinson's
disease,
multiple
sclerosis
(MS),
Alzheimer's
disease.The
sequelae
these
are
multifactorial.
For
instance,
strokes
not
only
predispose
individuals
to
arrhythmia
heart
failure
but
also
exacerbate
pre-existing
risk
factors.
Similarly,
epilepsy
is
autonomic
dysregulation
elevated
sudden
cardiac
death,
underscoring
necessity
for
vigilant
monitoring
in
affected
individuals.
disease
manifests
orthostatic
hypotension
sympathetic
denervation,
significantly
contributing
morbidity.
Additionally,
exhibit
dysfunction
heightened
risk,
need
proactive
management
strategies.Mechanistically,
conditions
disrupt
system
regulation,
incite
chronic
inflammation,
may
share
genetic
susceptibilities,
pathology.
Effective
complexities
requires
integrative
approach
includes
factor
modification,
pharmacotherapy,
lifestyle
interventions,
comprehensive
patient
education.Future
directions
include
identifying
novel
therapeutic
targets,
conducting
large-scale
clinical
trials,
investigating
biomarkers
individualize
treatment
strategies.
By
addressing
multifaceted
interactions
healthcare
providers
can
optimize
care,
reducing
morbidity
mortality
this
vulnerable
population.
Язык: Английский